Nakano M, Takeuchi M, Sugeno K
Nihon Yakurigaku Zasshi. 1980 Nov;76(8):729-35.
Effects of betamethasone, 17, 21-dipropionate (BMDP) and betamethasone (BM) on hypothalamo-pituitary-adrenal cortex axis following the intravenous or subcutaneous administration were studied in rats. The active site of the main metabolite of BMDP -- betamethasone 17-propionate (BMP) -- and BM was investigated by the stereotaxical implantation of these glucocorticoids. The ether-induced increase of plasma corticosterone was not suppressed by intravenous administration of BMDP in a dose of 300 mu g/kg, but BM suppressed this increase at doses over 10 mu g/kg. Subcutaneous administration of a large amount of these steroids (BMDP, 20 mg/kg; BM, 16 mg/kg) induced a significant suppression of the ether-induced plasma corticosterone increase. The implantation of the main metabolite of BMDP--BMP--into the anterior or medial hypothalamic area and septum was effective in significantly reducing the ether-induced increase of plasma corticosterone. BMP implants into the posterior hypothalamus or pituitary gland proved to be ineffective. In contrast, BM, when placed into the hypothalamic area (anterior, medial or posterior), septum or pituitary, lowered the plasma corticosterone levels.
研究了大鼠静脉或皮下注射倍他米松 17,21 - 二丙酸酯(BMDP)和倍他米松(BM)后对下丘脑 - 垂体 - 肾上腺皮质轴的影响。通过对这些糖皮质激素进行立体定位植入,研究了 BMDP 的主要代谢产物——倍他米松 17 - 丙酸酯(BMP)和 BM 的作用位点。静脉注射 300μg/kg 的 BMDP 并未抑制乙醚诱导的血浆皮质酮增加,但 BM 在剂量超过 10μg/kg 时可抑制这种增加。皮下注射大量这些类固醇(BMDP,20mg/kg;BM,16mg/kg)可显著抑制乙醚诱导的血浆皮质酮增加。将 BMDP 的主要代谢产物——BMP——植入下丘脑前部或内侧区域及隔区可有效显著降低乙醚诱导的血浆皮质酮增加。将 BMP 植入下丘脑后部或垂体无效。相比之下,将 BM 置于下丘脑区域(前部、内侧或后部)、隔区或垂体时,可降低血浆皮质酮水平。